tazarotene has been researched along with Freckle, Melanotic in 5 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malignant melanoma is a form of skin cancer associated with significant mortality once it has spread beyond the skin." | 2.50 | Interventions for melanoma in situ, including lentigo maligna. ( Apalla, Z; Chan, AW; Kyrgidis, A; Mocellin, S; Pilati, P; Tzellos, T, 2014) |
| "Imiquimod cream has been used off-label as monotherapy in the treatment of LM and may be used in the neoadjuvant setting prior to staged excision as a strategy to reduce the size of the surgical margins required to confirm negative histologic margins." | 1.48 | Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision. ( Bowen, GM; Bowling, M; Donigan, JM; Goldgar, DE; Hadley, ML; Hyde, MA, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chambers, M | 1 |
| Swetter, SM | 1 |
| Baker, C | 1 |
| Saunders, E | 1 |
| Chapman, MS | 1 |
| Donigan, JM | 1 |
| Hyde, MA | 2 |
| Goldgar, DE | 1 |
| Hadley, ML | 2 |
| Bowling, M | 1 |
| Bowen, GM | 2 |
| Tzellos, T | 1 |
| Kyrgidis, A | 1 |
| Mocellin, S | 1 |
| Chan, AW | 1 |
| Pilati, P | 1 |
| Apalla, Z | 1 |
| Tristani-Firouzi, P | 1 |
| Goldgar, D | 1 |
| Chimenti, S | 1 |
| Carrozzo, AM | 1 |
| Citarella, L | 1 |
| De Felice, C | 1 |
| Peris, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna[NCT00707174] | 90 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Negative histologic margins for the imiquimod plus tazarotene group compared to the imiquimod only group. (NCT00707174)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Imiquimod Only | 27 |
| Imiquimod and Tazarotene Combined | 29 |
1 review available for tazarotene and Freckle, Melanotic
| Article | Year |
|---|---|
Interventions for melanoma in situ, including lentigo maligna.
Topics: Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 2014 |
1 trial available for tazarotene and Freckle, Melanotic
| Article | Year |
|---|---|
A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Bio | 2012 |
3 other studies available for tazarotene and Freckle, Melanotic
| Article | Year |
|---|---|
Topical Imiquimod for Lentigo Maligna: Survival Analysis of 103 Cases With 17 Years Follow-up.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up | 2021 |
Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Female; Follow-Up | 2018 |
Treatment of lentigo maligna with tazarotene 0.1% gel.
Topics: Aged; Aged, 80 and over; Dermatologic Agents; Female; Gels; Humans; Hutchinson's Melanotic Freckle; | 2004 |